Category: Pricing

December 20, 2021

The price reduction for Aduhelm (aducanumab) comes into play from 1 January and comes on the back of the “feedback of our stakeholders,” said the biotech’s chief executive Michel Vounatsos. “Too many patients are not being offered the choice of […]

November 4, 2021

A new stripped back proposal has won over rebel Democrats whose earlier opposition led the plan to be shelved, despite being a longstanding pillar of Democrat policy and one of Joe Biden’s campaign pledges. Notable holdouts – including Senator Kyrsten […]

October 6, 2021

With Democrats in Washington debating the specifics of the president’s infrastructure program, the pharmaceutical industry may be able to squeak out a much-desired drug pricing win. As the negotiations unfold, Politico reports that the party leadership may have to abandon […]

September 14, 2021

The Senate and the FDA are appealing to the U.S. Patent and Trademark Office (USPTO) to examine how it can limit the ability of pharmaceutical companies to leverage patent strategies to extend their drug monopolies. In separate letters last week […]

August 13, 2021

The White House is looking to pay for some of its prime social and health initiatives by reducing outlays for prescription drugs, according to an announcement by President Biden that supports several leading drug-price control policies strongly backed by Democrats. […]

July 19, 2021

President Joe Biden’s executive order of July 9 included various steps toward making good on campaign promises to take on pharmaceutical companies by allowing the importation of prescription drugs and curbing the high cost of medicines. These issues were key […]

July 14, 2021

A chance for meaningful drug pricing reform is upon us, dozens of purchasers, healthcare and employer groups contend. But Congress needs to capitalize on its “time-limited” opportunity, or the problem could stagnate or worsen. In a letter to a bipartisan […]

June 24, 2021

In a joint statement with Aduhelm (aducanumab) development partner Eisai, Biogen said it is expecting slow take-up of the drug and an eligible patent population of around 1-2 million people with mild Alzheimer’s in the US, saying it has no […]

June 16, 2021

Federal agencies that regulate drug pricing and healthcare insurance are concerned that an industry practice of using rebates to lower drug costs for insurers has led to increases in list prices and out-of-pockets costs for patients. To investigate whether patients […]

May 7, 2021

The Biden-Harris Administration is backing a proposal from the World Trade Organization (WTO), supported by South Africa and India, that would temporarily remove IP protections on COVID-19 vaccines. The move itself is surprising, given that historically the US has been […]

March 12, 2021

Prometheus Biosciences, Inc. (Nasdaq: RXDX), a biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of inflammatory bowel disease (IBD), today announced the pricing of its […]

February 25, 2021

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced the pricing of its underwritten public offering of 12,500,000 shares of its common stock […]